The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia

• Main Authors: Choeyprasert,W., Pakakasama,S., Anurathapan,U., Songdej,D., Sirachainun,N., Sirireung,S., Panthangkool,W., Hongeng,S.
• Format: Article
• Published: Wiley-Blackwell 2015
• Subjects: Pediatrics, Perinatology and Child Health; Transplantation
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864621281&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38221
• Institution: Chiang Mai University

Allogeneic HSCT is the only curative treatment for severe thalassemia disease. MC occurs in one-third of these patients within the first two months after HSCT; this is a major risk factor of graft rejection, especially when RHCs are more than 25%. There is still no consensus for the management of MC...